Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
复制标题
DOI：
10.1016/s0140-6736(99)01122-8
复制
发表时间：
1999-03-13
期刊：
影响因子：
168.9
通讯作者：
Weber, R
中科院分区：
文献类型：
--
作者：
Ledergerber, B;Egger, M;Weber, R
背景高效抗逆转录病毒治疗（HAART）抑制HIV-1的疗效已得到充分证实。我们调查了HAART在常规practice.Methods的病毒学和临床结局，我们分析了前瞻性的数据，从瑞士艾滋病毒队列研究抑制病毒载量和进展艾滋病或死亡的2674门诊患者（中位年龄36岁，27.3%的妇女）谁开始HAART在1995-98年。病毒反弹定义为连续两次HIV-1-RNA测量值超过400拷贝/mL。我们分别分析了有抗逆转录病毒治疗史的患者和未接受过抗逆转录病毒治疗的患者的结果。
Background The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in routine practice.Methods We analysed prospective data from the Swiss HIV Cohort Study on suppression of viral load and progression to AIDS or death in 2674 outpatients (median age 36 years, 27.3% women) who started HAART in 1995-98. Viral rebound was defined as two consecutive HIV-1-RNA measurements of more than 400 copies/mL. We analysed separately outcomes in patients with a history of antiretroviral treatment and in treatment-naive patients.Findings An estimated 90.7% of treatment-naive patients reached undetectable viral load (